Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization.
about
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designHydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoterMassive accidental overdose of hydroxyurea in a young child with sickle cell anemiaPreclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.Enhancement of human chorionic gonadotrophin production by antimetabolites.Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 studyDevelopment of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.Hydroxyurea: a key player in cancer chemotherapy.Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I.The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
P2860
Q28289090-E5536AB9-0B7C-42AD-A6EA-2A0FD34301EFQ28344235-EBDC73BE-BE79-46CD-980B-C2BD1FBDDBF7Q35353627-07A42E8E-4418-4FBD-8A91-E2AE36B07C3CQ35751401-CD51EE11-7826-49AB-89F5-FFB563AA350CQ35976435-823DE04F-0270-4186-AD0E-90E336623F17Q36046693-8C8F9641-B072-40BB-966D-B966AA015C07Q36148689-1ECE6779-D28F-4FE0-9688-B757BE9E4AEDQ36706798-4CCB5361-C45F-4CBF-B35F-B59B789DC2FBQ37965630-60CD06BC-1F57-46A8-A9CD-7244171148ADQ40037984-E4CEDD84-85CB-4A0E-8884-0542AC5195CBQ44497994-56A33814-8082-4736-8968-60D42FC72FDBQ45767503-2732E0AD-4332-4EF7-B0DA-FC06D2CFBAFAQ46391225-E7BA9F47-3A17-4704-BD28-434490A603B9Q46922191-E1EA0879-F828-45B0-B32F-CB6D07B832C5
P2860
Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization.
description
1980 nî lūn-bûn
@nan
1980 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@ast
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@en
type
label
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@ast
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@en
prefLabel
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@ast
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@en
P2093
P1433
P1476
Studies of hydroxyurea adminis ...... ics, and cell synchronization.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO;2-N
P407
P577
1980-08-01T00:00:00Z